{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:00:04Z","timestamp":1777899604469,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"33","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.vaccine.2017.06.044","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:48:13Z","timestamp":1498693693000},"page":"4099-4104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I\/II, prospective, randomized, open-label trial"],"prefix":"10.1016","volume":"35","author":[{"given":"Un-In","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Sen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiang-Chi","family":"Kung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsong-Yih","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu-Lun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Te-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.06.044_b0005","unstructured":"US Centers for Disease Control and Prevention. Influenza Risk Assessment Tool (IRAT). Available at: <https:\/\/www.cdc.gov\/flu\/pandemic-resources\/national-strategy\/risk-assessment.htm> [accessed Feb 27 2017]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0010","unstructured":"World Health Organization. Human infection with avian influenza A(H7N9) virus \u2013 China. Available at: <http:\/\/www.who.int\/csr\/don\/20-february-2017-ah7n9-china\/en\/> [accessed Feb 2017]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0015","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1304459","article-title":"Human infection with a novel avian-origin influenza A (H7N9) virus","volume":"368","author":"Gao","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.06.044_b0020","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0140-6736(13)60943-5","article-title":"The first case of H7N9 influenza in Taiwan","volume":"381","author":"Chang","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.06.044_b0025","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jinf.2013.08.003","article-title":"Serological survey in close contacts with a confirmed case of H7N9 influenza in Taiwan","volume":"67","author":"Hsieh","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2017.06.044_b0030","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/ncomms3854","article-title":"Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility","volume":"4","author":"Hai","year":"2013","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2017.06.044_b0035","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/S0140-6736(13)61209-X","article-title":"Oseltamivir resistance during treatment of H7N9 infection","volume":"381","author":"Hay","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.06.044_b0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/infdis\/jiu447","article-title":"Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan","volume":"211","author":"Marjuki","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.044_b0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nature04795","article-title":"Strategies for mitigating an influenza pandemic","volume":"442","author":"Ferguson","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2017.06.044_b0050","unstructured":"Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull World Health Organ 1995;73:431\u20135."},{"key":"10.1016\/j.vaccine.2017.06.044_b0055","doi-asserted-by":"crossref","first-page":"e0120793","DOI":"10.1371\/journal.pone.0120793","article-title":"Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets","volume":"10","author":"Chia","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.06.044_b0060","unstructured":"World Health Organization. Serological detection of avian influenza A(H7N9) virus infections by modified horse red blood cells haemagglutination-inhibition assay. Available at: <http:\/\/www.who.int\/influenza\/gisrs_laboratory\/cnic_serological_diagnosis_hai_a_h7n9_20131220.pdf> [accessed 2016 Oct]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0065","unstructured":"World Health Organization. WHO manual on animal influenza diagnosis and surveillance. Available at: <http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/en\/whocdscsrncs20025rev.pdf>."},{"key":"10.1016\/j.vaccine.2017.06.044_b0070","unstructured":"World Health Organization. Serological detection of avian influenza A(H7N9) infections by microneutralization assay. Available at: <http:\/\/www.who.int\/influenza\/gisrs_laboratory\/cnic_serological_diagnosis_microneutralization_a_h7n9.pdf> [accessed Oct 2016]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0075","unstructured":"European Committee for Proprietary Medicinal Products, European Medicines Agency. CHMP recommendations for the pharmacovigilance plan as part of the risk management plan to be submitted with the marketing authorisation application for a pandemic influenza vaccine. Available at: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2010\/01\/WC500051739.pdf> [accessed Oct 2016]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0080","unstructured":"Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Available at: <http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm091985.pdf> [accessed Oct 2016]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0085","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/infdis\/jiv056","article-title":"Safety and immunogenicity of a subvirion monovalent unadjuvanted inactivated influenza A(H3N2) variant vaccine in healthy persons >\/=18 years old","volume":"212","author":"Keitel","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.044_b0090","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.06.044_b0095","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.06.044_b0100","doi-asserted-by":"crossref","unstructured":"Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-Thasan N. A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014;6:234ra55.","DOI":"10.1126\/scitranslmed.3008761"},{"key":"10.1016\/j.vaccine.2017.06.044_b0105","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMc1313186","article-title":"A recombinant viruslike particle influenza A (H7N9) vaccine","volume":"369","author":"Fries","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.06.044_b0110","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1473-3099(15)00425-9","article-title":"Live-attenuated H7N9 influenza vaccine is weak, yet strong","volume":"16","author":"Zanin","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.044_b0115","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/infdis\/jiv526","article-title":"Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9)","volume":"213","author":"Sobhanie","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.044_b0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(15)00378-3","article-title":"H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Rudenko","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.06.044_b0125","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1056\/NEJMoa073121","article-title":"A clinical trial of a whole-virus H5N1 vaccine derived from cell culture","volume":"358","author":"Ehrlich","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.06.044_b0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1750-2659.2009.00082.x","article-title":"A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models","volume":"3","author":"Cox","year":"2009","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2017.06.044_b0135","doi-asserted-by":"crossref","first-page":"6901","DOI":"10.1128\/JVI.03520-12","article-title":"Replication and immunogenicity of swine, equine, and avian h3 subtype influenza viruses in mice and ferrets","volume":"87","author":"Baz","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2017.06.044_b0140","unstructured":"World Health Organization. Aluminum adjuvants. Available at: <http:\/\/www.who.int\/vaccine_safety\/committee\/topics\/adjuvants\/Jun_2012\/en\/> [accessed Nov 2016]."},{"key":"10.1016\/j.vaccine.2017.06.044_b0145","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants \u2013 in retrospect and prospect","volume":"22","author":"Lindblad","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.044_b0150","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.1016\/j.vaccine.2011.09.124","article-title":"Updated aluminum pharmacokinetics following infant exposures through diet and vaccination","volume":"29","author":"Mitkus","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.044_b0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0042-6822(85)90105-9","article-title":"Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs","volume":"143","author":"Robertson","year":"1985","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.06.044_b0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0042-6822(87)90040-7","article-title":"Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus","volume":"160","author":"Robertson","year":"1987","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.06.044_b0165","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1016\/j.vaccine.2009.06.024","article-title":"Use of MDCK cells for production of live attenuated influenza vaccine","volume":"27","author":"Liu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.06.044_b0170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00253-010-2973-9","article-title":"Development and strategies of cell-culture technology for influenza vaccine","volume":"89","author":"Feng","year":"2011","journal-title":"Appl Microbiol Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17308319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T08:51:13Z","timestamp":1535705473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17308319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":34,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0264410X17308319"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.044","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I\/II, prospective, randomized, open-label trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}